Five FDA Dog Drug Approvals to Know About From the Past Year

At a glance

• The FDA’s Center for Veterinary Medicine announced several notable approvals for dogs between December 2025 and October 2026.
• All five medicines below are prescription-only, so decisions about them belong with your vet.

The five approvals

1. Tessie (tasipimidine), May 6, 2026. Described by the FDA as the first drug approved for noise aversion and separation anxiety in dogs. It is an oral solution made by Orion Corporation, given before the trigger or before the dog is left alone ¹.
2. Laverdia (verdinexor), January 16, 2026. Full approval of the first oral treatment for lymphoma in dogs, made by Anivive Lifesciences. It had held a conditional approval since January 2021 ².
3. KBroVet (potassium bromide), January 21, 2026. Full approval of a chewable tablet to control seizures in dogs with idiopathic epilepsy, made by Pegasus Laboratories, after a conditional approval in 2021 ³.
4. Vetmedin (pimobendan), December 19, 2025. A new indication for an existing drug: delaying the onset of congestive heart failure in dogs with a particular stage of preclinical mitral valve disease. The FDA called it the first full approval of an indication that began as an expanded conditional approval ⁴.
5. Convenia RTU (cefovecin), October 20, 2026. A ready-to-use injectable from Zoetis for certain bacterial skin infections in dogs. Unlike the original Convenia, the new formulation is for dogs only, because it contains ingredients that may be toxic to cats ⁵.

What “full” and “conditional” mean

A conditional approval lets a drug reach patients while the maker finishes proving effectiveness. A full approval means those requirements were met. The FDA pages for items 2, 3 and 4 describe full approvals that followed conditional ones ^2,3,4. The pages for items 1 and 5 say “approved” without saying whether the approval is full or conditional.

What owners should do

These announcements are information, not recommendations. Your veterinarian knows your dog’s history and can tell you whether any of these options is appropriate. For separation anxiety, behavior training remains central: see our training handbook.

This roundup reflects the FDA’s updates as of November 8, 2026. The FDA’s Center for Veterinary Medicine page is the authoritative, current source.